



FOR IMMEDIATE RELEASE

Ernest J. Schenk, Manager, Investor Relations and Communication
(269) 673-9212
E-mail: Investor@perrigo.com

**PERRIGO COMPANY ANNOUNCES TENTATIVE
APPROVAL FOR GLIMEPIRIDE TABLETS**

ALLEGAN, Mich. – Aug. 25, 2005 – The Perrigo Company (Nasdaq: PRGO; TASE) today announced that, through a partnership with InvaGen Pharmaceuticals, it has received tentative approval from the U.S. Food and Drug Administration (FDA) to market Glimepiride Tablets, 1 mg, 2 mg and 4 mg. Final approval is anticipated upon brand patent expiration on October 6, 2005.

The product is the AB-rated equivalent to Aventis' Amaryl® Tablets, 1 mg, 2 mg and 4 mg, indicated for the treatment of diabetes.

Annual sales for the brand are approximately \$350 million, according to IMS data.

The Perrigo Company is a leading global healthcare supplier and the world's largest manufacturer of over-the-counter (OTC) pharmaceutical and nutritional products for the store brand market. Store brand products are sold by food, drug, mass merchandise, dollar store and club store retailers under their own labels. The Company also develops, manufactures and markets prescription generic drugs, active pharmaceutical ingredients and consumer products, and operates manufacturing facilities in the United States, Israel, United Kingdom, Mexico and Germany. Visit Perrigo on the Internet (<http://www.perrigo.com>).

###